CENTENNIAL, Colo., August 24, 2016 – Cell>Point today announced it has entered into license
agreements with Vyripharm Biopharmaceuticals for the use of its In-Situ Hydrogel, N4 Technology and
Oligosaccharide (Dual Agent) Technology to develop applications in combination with cannabinoids for
nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, posttraumatic
stress disorder (“PTSD”), epilepsy and other acute/chronic disorders. As part of the license
Cell>Point will own a majority interest in Vyripharm Biopharmaceuticals.
About Cell>Point, L.L.C.
Cell>Point is a biopharmaceutical company focused on the development of universal molecular imaging compounds and molecular therapeutics for the diagnosis, staging, treatment and treatment monitoring of cancer, cardiovascular disease, and a range of ischemic diseases. Cell>Point has exclusive licenses to five drug-development platforms, all from The University of Texas MD Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point’s product candidates and licenses, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The Company has offices in Centennial, Colo. and Houston, Texas.
About Vyripharm Biopharmaceuticals, L.L.C
Vyripharm Biopharmaceuticals is a Delaware limited liability company formed in 2014 for the purpose of treating neurological disorders and cancers. The Company has established a proprietary comprehensive analytical testing, monitoring and tracking system program that it believes will become the standard accepted methodology to help create stability and predictability in the emerging business of medical cannabinoids. The Company will also develop applications (using in-licensed proprietary technologies in combination with cannabinoids) for nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, post-traumatic stress disorder (“PTSD”), epilepsy and other acute/chronic disorders. The company is located in Houston, Texas.